Identification of Smad2 and Smad3 specific binding sites in a breast cancer cell line model

We identify Smad2 and Smad3 specific binding site in a breast cancer breast cell model MDA-MB-231 using LAP-tag GFP fusion proteins under the control of endogenous regulatory elements. Stable cell lines were generated via transfection with a BAC followed by antibiotics selection. We show that LAP-fused SMad2/3 can be used to recapitulate native TGFB signaling. Smad2/Smad3 specific binding sites were identified by ChIP-seq against GFP before and after TGFB treatment. Genomic DNA was sequenced via single end sequencing on Illumina HiSeq Overall design: Chromatin immunoprecipitation against GFP in fusion protein before and after TGFB treatment